Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd (NLSP) delivers cutting-edge therapies for central nervous system disorders through innovative platforms like its dual orexin receptor agonist (DOXA) technology. This page provides essential updates for stakeholders tracking clinical developments, strategic partnerships, and regulatory milestones in neuropharmaceutical research.
Access verified press releases and analysis on NLSP's progress in addressing narcolepsy, neurodegenerative diseases, and cognitive disorders. Our curated news collection covers clinical trial results, intellectual property developments, and financial performance updates critical for informed decision-making.
Key content includes updates on the Kadimastem merger's therapeutic pipeline expansion, DOXA platform validation studies, and collaborative research initiatives. Investors will find timely reports on funding rounds, patent approvals, and preclinical data disclosures.
Bookmark this page for consolidated access to NLSP's latest advancements in CNS therapy development. Regularly updated to reflect material events and scientific breakthroughs, it serves as your primary resource for understanding the company's position in competitive biopharmaceutical markets.
NLS Pharmaceutics (NLSP) announced the initial closing of $500,000 from a previously announced $1 million financing agreement with an accredited investor. The shares were priced at $3.10, representing a 48% premium above the market closing price as of January 6, 2025. This financing, combined with a previous $3.2 million investment from October 2024, supports the proposed merger with Kadimastem
The financing agreement, dated December 4, 2024, involves no warrants and received approval at NLS's extraordinary general meeting on January 7, 2025. NLS has filed an F-4 Registration Statement with the SEC detailing the proposed merger with Kadimastem, which aims to create a combined Nasdaq-traded biotechnology company focusing on advanced clinical-stage product candidates.
NLS Pharmaceutics (NLSP) and Kadimastem announced the filing of an F-4 Registration Statement with the SEC for their proposed merger. The transaction aims to create a Nasdaq-traded biotechnology company focusing on advanced clinical-stage product candidates and allogeneic cell therapy platform development.
The Registration Statement includes a prospectus for the merger and a proxy statement for NLS shareholders' meeting. This follows the November 5, 2024 announcement of their binding merger agreement. The merger completion requires approval from both companies' shareholders, SEC effectiveness declaration of the Registration Statement, and other customary closing conditions.
Through this merger, Kadimastem plans to become publicly traded on Nasdaq. The combined entity will focus on rare and complex central nervous system disorders, neurodegenerative diseases, and potential diabetes treatments.
NLS Pharmaceutics (NLSP) and Kadimastem announced the submission of a Pre-IND meeting request to the FDA for iTOL102, a potential breakthrough Type 1 Diabetes treatment. The therapy combines Kadimastem's IsletRx (insulin-producing islet cells) with iTolerance's iTOL-100 immunomodulator technology. IsletRx is derived from human stem cells and can detect glucose levels and produce insulin and glucagon. The treatment showed promising results in preclinical studies at the University of Miami's Diabetes Research Institute, demonstrating functional insulin release and disease reversal in animal models. The companies are working to complete their merger by the end of January 2025.
NLS Pharmaceutics (NLSP) CEO Alex Zwyer issued a shareholder letter highlighting recent developments and future strategies. The company has made progress with its Dual Orexin Receptor Agonist (DOXA) platform, developing AEX-41 and AEX-2 compounds for narcolepsy treatment. Preliminary results from AEX-41 studies showed promising outcomes in managing sleep-wake disturbances.
The company regained Nasdaq compliance and strengthened its financial position through two private placements: a $3.2 million placement in October and an announced $1 million placement at $3.10 per share in December. These funds extend the runway to approximately 18 months.
NLSP announced a merger with Kadimastem, expected to close by January 2025. Post-merger, Kadimastem will own DOXA program, while NLSP shareholders will retain rights to benefit from potential sale of legacy assets, including Mazindol, through a CVR agreement.
NLS Pharmaceutics (Nasdaq: NLSP) announced a private placement offering of up to 322,580 common shares at $3.10 per share, representing a 15% premium to market price, for total gross proceeds of up to $1.0 million. The offering will be executed in two tranches: an initial closing of $500,000 expected by January 10, 2025, and a potential subsequent closing of another $500,000 within 15 days following specific conditions, including shareholder approval and maintaining share price above $3.10 for ten consecutive trading days. The company plans to use proceeds for general corporate purposes.
NLS Pharmaceutics (NASDAQ:NLSP) announced promising preclinical data for its dual orexin receptor agonist (DOXA) platform. The study focuses on AEX-41 and AEX-2, first-in-class non-sulfonamide DOXAs targeting both orexin-1 and orexin-2 receptors while inhibiting cathepsins. In orexin knockout mice, AEX-41 showed significant increase in wakefulness and reduced REM sleep duration, with efficacy comparable to existing OX2R agonists. The company plans to expand research in 2025 to study neuroinflammation impact, with an IND application planned for 2026-2027. The dual-action mechanism could potentially address both sleep-wake regulation and neurodegenerative processes.
NLS Pharmaceutics has provided insights into its preclinical program evaluating dual orexin receptor agonist (DOXA) platform. The company is developing AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs targeting both orexin-1 and orexin-2 receptors while inhibiting cathepsins. The ongoing studies at the Centre for Neuroscience Research of Lyon use an orexin knockout mouse model to evaluate wakefulness promotion, sleep quality enhancement, and cataplexy suppression. The study employs EEG/EMG technology and includes stress condition testing. First results are expected in early December 2024, with potential applications extending to other conditions like ALS.
NLS Pharmaceutics (NASDAQ:NLSP) and Kadimastem have announced a definitive merger agreement to combine their companies. The merger will focus on advancing NLS's Dual Orexin Agonist platform and Kadimastem's allogeneic cell therapy program. Post-merger, NLS plans to divest its legacy assets except for DOXA, with proceeds distributed to shareholders. The initial target share split is 85% Kadimastem/15% NLS, but current estimates suggest 80%/20% based on NLS's recent financing. The merger is expected to close in January 2025, subject to shareholder and Nasdaq approval. Kadimastem plans to initiate Phase IIa trials for ALS treatment and progress its diabetes program with a pre-IND submission in Q1 2025.
NLS Pharmaceutics (Nasdaq: NLSP) announced it has regained full compliance with Nasdaq listing requirements. The company received notice from Nasdaq confirming compliance with both the bid price requirement (Rule 5550(a)(2)) and equity requirement (Rule 5550(b)(1)). The compliance was achieved through balance sheet improvements, including capital raising and implementation of a reverse share split.
NLS Pharmaceutics (NASDAQ:NLSP) has secured a key patent in Japan for Mazindol ER in the treatment of heroin dependence. The patent covers the use of extended-release Mazindol for opioid use disorder, offering a new therapeutic strategy. Mazindol, a tetracyclic compound, has shown promising results in reducing heroin dependence by modulating neurotransmitter systems involved in reward signaling and addiction pathways.
Unlike traditional opioid treatments, Mazindol works by indirectly modulating the brain's reward systems, targeting opioid receptors without inducing the same level of dependence. The sustained-release formulation allows for steady drug release, improving patient compliance and reducing relapse risk. The patent includes eight claims, providing robust protection for Mazindol ER's use in treating opioid dependence in Japan.
